On the Frontlines of Non-Small Cell Lung Cancer
Catch up on the latest updates on non-small cell lung cancer treatment from the 2024 American Society of Clinical Oncology Annual Meeting, the World Conference on Lung Cancer, and the European Society for Medical Oncology Congress in this exclusive conference coverage series.
- Update frequency
- every 3 days
- Episodes
- 8
- Years Active
- 2024 - 2025
Evaluating Dato-DXd for EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis
Guest: Elaine Shum, MD
Guest: Estelamari Rodriguez, MD, MPH
There was a recent pooled analysis of the TROPION-Lung01 and TROPION-Lung05 studies, which focused …
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings
Guest: Julia Rotow, MD
In non-squamous non-small cell lung cancer (NSCLC), a small percentage of patients will have activating HER2 mutations. For these patients, …
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
Guest: Laura Alder, MD
The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-li…
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results
Guest: Thomas Egenod, MD
In an effort to identify additional treatment options for resectable non-small cell lung cancer (NSCLC), the NeoCOAST-2…
Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial
Guest: Alex Spira, MD, PhD, FACP
Valemetostat is a novel therapy that’s demonstrated clinical efficacy and safety across multiple hematologic malignancies, but wha…
Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases
Guest: Aaron Lisberg, MD
Unfortunately, brain metastases are very common in patients with non-small cell lung cancer (NSCLC). That’s why the phase 3 TROPION-Lung01…
Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01
Guest: Aaron Lisberg, MD
Docetaxel alone or in combination with ramucirumab is the current standard of care for the second-line treatment of non-small cell lung ca…
NSCLC Care: Predicting Response to Dato-DXd with a TROP2 Biomarker
Guest: Marina Garassino, MD
Datopotamab deruxtecan (Dato-DXd) is a second-line antibody drug conjugate that could lead to improved progression-free survival in pat…